Q32 Bio Inc. · Drugmakers

QTTB

Elevated riskNext report: Around Nov 12 (est.)

View price ↗

The short version

A profitable company. Institutions are adding.

Going well

Profitable, keeps 56% of sales as profit
Little debt
High return on equity: 125%

Money moves

Insiders sold $45K in the last 30 days
Institutions added 135% to their holdings in the quarter ending June 2026 (45 bought, 21 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$8.46-2.0% that day

Company value: $252M; Share price times all shares
Price vs profit (P/E): 2.7x; You pay about $3 for each $1 of yearly profit
Price vs sales: 4.7x; Company value is 4.7 times a year of sales
Cash vs value: 42%; A big cushion: cash is a large part of what the company is worth
Debt vs value: 1%; Debt as a share of company value

From QTTB's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

Not reported

Sep '23Tap a barJun '26

Over 5 years, sales grew about 82% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of QTTB. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +82% a yearProfit margin50%Last 12 months: 62.8%P/E at the end8xToday: 2.7x. Many steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$200M

Profit in 5 years$100M

Price these guesses point to$26.81+217% vs $8.46 todayAbout +26% a year, before dividends

What today's price needs: with a 50% margin and a 8x P/E, sales would have to grow about 3.2% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

3/5Mixed

PassReturn on equity 15%+Earns a lot on the money owners have in the business.125.0%
PassDebt under half of equityNot relying on borrowed money.0.08x equity
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.55.5%
MissProfitable every yearSteady profits, not one good year.1 of 9 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$33.5M

Revenue: $53.7M
5-year growth: +81.9%/yr; revenue, per year
Total debt: $3.5M; 0.08x equity
Current ratio: 4.85x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 5

EPS: -$0.44; vs -$0.78
Free cash flow: -$3.1M
Share count: +66.8%; vs a year ago

Insider rating

Last 90 days

36Selling

3 insiders sold $45K (not pre-planned)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.2
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+135.4%

Institutions added 135.4% to their holdings. 45 bought, 21 sold. 2 quarters of net buying in a row.

Shares held by institutions22.2M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+37.2%

Cash runwayAt last year's cash burn

38 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

30M

Why elevated risk

Share count growing 37.2% a year (dilution)
6 offering filings in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportAround Nov 12 (est.)Estimated from the same quarter last year

Results filedAug 5
Results filedMay 5
Results filedMar 10
Results filedNov 13, 2025
Results filedAug 6, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

New 5%+ holder (passive)Oct 9 · View filing ↗Big holder 5%+ holder update (passive)Aug 14 · View filing ↗Big holder 5%+ holder update (passive)Aug 14 · View filing ↗Big holder 5%+ holder update (passive)Jul 31 · View filing ↗Big holder Offering prospectusJul 28 · View filing ↗Offering Shelf offering registrationJul 17 · View filing ↗Offering Offering prospectusJul 15 · View filing ↗Offering Offering prospectusJul 13 · View filing ↗Offering Shelf offering registrationJun 25 · View filing ↗Offering Major agreementMay 27 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$45K3 insiders, 0 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Jodie Pope MorrisonCEO	Sell	3K	$8.32	$27K	340K	Oct 6Filing ↗
-0.9% of their holdings Not a pre-planned sale Also Director Filed 8 days after
Shelia M. VioletteChief Scientific Officer	Sell	917	$8.32	$8K	127K	Oct 6Filing ↗
-0.7% of their holdings Not a pre-planned sale Filed 8 days after
Lee KalowskiCFO and President	Sell	1K	$8.32	$11K	137K	Oct 6Filing ↗
-0.9% of their holdings Not a pre-planned sale Filed 8 days after